Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by CENTRAL TRUST Co

CENTRAL TRUST Co cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 56.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 519 shares of the biopharmaceutical company’s stock after selling 673 shares during the period. CENTRAL TRUST Co’s holdings in Regeneron Pharmaceuticals were worth $292,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Brighton Jones LLC raised its position in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $226,000. MGO One Seven LLC increased its stake in shares of Regeneron Pharmaceuticals by 28.1% in the second quarter. MGO One Seven LLC now owns 483 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 106 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its holdings in Regeneron Pharmaceuticals by 22.5% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 2,169 shares of the biopharmaceutical company’s stock valued at $1,139,000 after acquiring an additional 398 shares in the last quarter. Finally, Axxcess Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at $230,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the transaction, the director owned 17,803 shares in the company, valued at $13,860,169.59. This represents a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,636 shares of company stock valued at $2,862,920. Company insiders own 7.02% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. HSBC raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Cantor Fitzgerald increased their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. UBS Group boosted their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Finally, JPMorgan Chase & Co. upped their price target on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $803.17 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The firm has a fifty day moving average of $762.17 and a 200-day moving average of $666.58. The company has a market cap of $84.91 billion, a price-to-earnings ratio of 19.33, a price-to-earnings-growth ratio of 2.16 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the firm posted $12.07 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a $0.94 dividend. The ex-dividend date is Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is currently 8.47%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.